Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

  title={Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines},
  author={Ronald A. Asherson and Ricard Cervera and Philip G. de Groot and Doruk Erkan and Marie Claire Boffa and J C Piette and Munther A. Khamashta and Yehuda Shoenfeld},
  pages={530 - 534}
The term ‘catastrophic’ antiphospholipid syndrome (APS) is used to define an accelerated form of APS resulting in multiorgan failure. Although catastrophicAPS patients represent less than 1% of all patients with APS, they are usually in a life-threatening medical situation that requires high clinical awareness. The careful and open discussion of several proposals by all participants in the pre-symposium workshop on APS consensus, held in Taormina on occasion of the 10th International Congress… 

Figures and Tables from this paper

Diagnosing catastrophic antiphospholipid syndrome: the necessity for clinical awareness

The catastrophic variant of antiphospholipid syndrome (APS) is the most severe form of the syndrome and is now also referred to as Asherson’s syndrome, thus honoring the author who passed away in 2008.

Treatment of catastrophic antiphospholipid syndrome.

Attention to associated diagnoses, such as infection and systemic lupus erythematosus (SLE), is critical at the time of diagnosis, and all patients should be treated with anticoagulants, corticosteroids, and possibly plasma exchange.

Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease

The diagnostic challenges and the recently updated diagnostic algorithms for CAPS are summarized providing a ‘step-by-step’ approach for clinicians (and researchers) in the assessment of patients with multiple organ thromboses.

CAPS Registry

An international registry of patients with catastrophic APS (CAPS Registry) was created in 2000 by the European Forum on aPL, and the analysis of this registry has allowed the characterization of the clinical and laboratory features of the catastrophic APs as well as the establishment of preliminary criteria for its classification and guidelines for its management.

Clinical and Laboratory Features of the Catastrophic Antiphospholipid Syndrome

The majority of patients presented with multiple organ involvement at the time of CAPS, and the combination of pulmonary, cardiac, and renal involvement was most commonly seen.

Diagnosis and management of catastrophic antiphospholipid syndrome

The diagnostic challenges and current approaches to the treatment of CAPS are discussed, including its pathophysiology, clinical manifestations, diagnostic approaches, differential diagnoses, management and treatment of relapsing CAPS, and its prognosis.

Task Force Report on Catastrophic Antiphospholipid Syndrome

The first-line treatment should include the combination of anticoagulation against thrombosis plus glucocorticoids against the manifestations of SIRS plus plasma exchange and/or intravenous immunoglobulins to remove or block the antiphospholipid antibodies and the cytokines involved in the SirS.

Catastrophic Antiphospholipid Syndrome

Although less than 1% of patients with the antiphospholipid syndrome develop the catastrophic variant, its potentially lethal outcome emphasizes its importance in clinical medicine today and it is expected that the periodical analysis of these data will allow us to increase the authors' knowledge of this condition.

Catastrophic antiphospholipid syndrome presenting with sudden renal failure: The lesson lies in vascular lesions.

The case presented in this issue of Journal of Nephropatholgy by Mardani et al represents a de novo CAPS, at least on the face of it, and the current complication of CAPS seems most probably to be superimposed on the background of hitherto undiagnosed APS.



Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.

It is essential that this syndrome should be diagnosed early and treated aggressively and the combination of high doses of heparin and corticosteroids plus intravenous gamma globulins or plasmapheresis is proposed as the treatment of choice in patients with this severe condition.

Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients

The clinical and serologic features of the largest series of patients with catastrophic APS hitherto reported are described, including 30 new cases from interested physicians in many different countries, as well as a comprehensive literature review of 50 additional recently published case reports with this syndrome.

Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients

The majority of patients manifested microangiopathy--that is, occlusive vascular disease affecting predominantly small vessels of organs, particularly kidney, lungs, brain, heart, and liver--with a minority of patients experiencing only large vessel occlusions.

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

An association with SLE, the patient's sex, and the patient’s age at disease onset can modify the disease expression and define specific subsets of APS.

The Catastrophic Antiphospholipid Syndrome

The addition of the word “catastrophic” to the term antiphospholipid syndrome (APS) was proposed 20 years ago by Ronald Asherson when he published an editorial describing a group of patients who develop multiple thrombosis in a short period of time.

Thrombotic storm: when thrombosis begets thrombosis.

  • C. Kitchens
  • Medicine
    The American journal of medicine
  • 1998

international consensus statement

Around that time, a number of learned scientific articles began to appear in the medical literature, par­ ticularly in the United States, showing just how diffi­ cult it was to prove causation.

Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases.

It is believed that infection plays a significant role in the pathogenesis and amplification of the antiphospholipid syndrome and in certain patients, this association probably is mediated via immune mechanisms, which also enhance the genesis of atherosclerosis.